CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 08/13/19

- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based o...

BERKELEY HEIGHTS, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2019 financial results ...

BERKELEY HEIGHTS, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient in a Phase 1/2 st...

The following healthcare companies have recently filed for mixed shelf offerings: More news on: Unity Biotechnology, Inc., Kiniksa Pharmaceuticals, Ltd., Evelo Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) initiated with Buy rating and $8 (1173% upside) price target at Roth Capital Partners. More news on: Cyclacel Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Fate Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Start Time: 16:30 End Time: 16:50 Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2019 Earnings Conference Call May 14, 2019, 16:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO and Secretary Judy Chiao - VP, Clinical Development ...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q1 GAAP EPS of -$0.14 beats by $0.08 . More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlig...

BERKELEY HEIGHTS, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2019 financial results on...

Nano cap Cyclacel Pharmaceuticals ( CYCC -3.9% ) slips on average volume in response to results from a Phase 1 clinical trial evaluating a sequential regimen of sapacitabine and seliciclib in patients with BRCA-positive metastatic breast cancer. The data, apparently underwhelming to in...